Moderna's chief executive. He stressed however that the mRNA-1273.214 candidate – which combines the current SpikeVax booster with an Omicron-specific candidate – is the company's lead ...

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. Let's discuss the pros and cons of buying Moderna stock.

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

Moderna's partnership with Merck in personalized cancer therapies and promising Phase III trials support a speculative 'Buy' for long-term investors with high-risk tolerance. Despite a tough 2024 ...

Moderna gains HHS backing for developing mRNA-based pandemic influenza vaccines, advancing clinical studies for up to five subtypes. Get the Real Story Behind Every Major Earnings Report Tuesday ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it.

Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial ...

Moderna's (NASDAQ: MRNA) sales are slowing down, and Moderna stock is going down -- a lot. The coronavirus vaccine maker's shares plunged 21.2% through 10:20 a.m. ET Monday after it updated ...

Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19 ...

Moderna shares will likely remain under scrutiny after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion. The stock broke down from a two ...